{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:27:58Z","timestamp":1790756878418,"version":"4.1.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>Corneal neovascularization is an important risk factor for graft rejection after keratoplasty, although its role in posterior lamellar keratoplasty is not yet well defined. The aim of this work was to describe clinically available approaches that target corneal neovascularization preoperatively to improve graft survival after subsequent penetrating keratoplasty (PK) and to present findings on Descemet membrane endothelial keratoplasty (DMEK) in eyes with neovascularization.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Recent work on the use of anti-vascular endothelial growth factor agents, fine needle diathermy (FND), and corneal collagen crosslinking (CXL) to regress corneal neovascularization before PK is summarized. Furthermore, studies that have investigated the outcome of DMEK in vascularized eyes are presented.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Pretreatment of recipient corneas with FND combined with anti-vascular endothelial growth factor agents is an effective method to reduce long-standing corneal neovascularization and results in relatively low rejection rates after subsequent high-risk PK. Peripheral CXL also seems to be a potent method to regress corneal neovascularization, although data on the impact of pretransplant CXL on long-term graft survival are not yet available. There are only limited data on graft rejection rates after DMEK in vascularized eyes, but initial studies indicate that DMEK seems to be a viable therapeutic option when no stromal scars are present. Furthermore, preexisting stromal neovascularization seems to regress after high-risk DMEK.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Several angioregressive strategies to treat corneal neovascularization before PK have entered the clinic with promising initial results, which warrants larger trials with longer follow-up. Studies will also have to define the precise role of preexisting corneal neovascularization in high-risk DMEK.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ico.0000000000002736","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T19:21:35Z","timestamp":1623439295000},"page":"1512-1518","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":23,"title":["Cutting Edge: Novel Treatment Options Targeting Corneal Neovascularization to Improve High-Risk Corneal Graft Survival"],"prefix":"10.1097","volume":"40","author":[{"given":"Claus","family":"Cursiefen","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University of Cologne, Faculty of Medicine, University Hospital Cologne, Cologne, Germany; and"},{"name":"Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Hos","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Cologne, Faculty of Medicine, University Hospital Cologne, Cologne, Germany; and"},{"name":"Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,6,8]]},"reference":[{"key":"R1-20250728","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/ACI.0b013e32833dfa11","article-title":"High-risk corneal allografts and why they lose their immune privilege","volume":"10","author":"Niederkorn","year":"2010","journal-title":"Curr Opin Allergy Clin Immunol."},{"key":"R2-20250728","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.ophtha.2010.01.039","article-title":"Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis","volume":"117","author":"Bachmann","year":"2010","journal-title":"Ophthalmology."},{"key":"R3-20250728","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1111\/ajt.14874","article-title":"UV light crosslinking regresses mature corneal blood and lymphatic vessels and promotes subsequent high-risk corneal transplant survival","volume":"18","author":"Hou","year":"2018","journal-title":"Am J Transpl."},{"key":"R4-20250728","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.1038\/s41598-018-24037-3","article-title":"Fine needle-diathermy regresses pathological corneal (Lymph)Angiogenesis and promotes high-risk corneal transplant survival","volume":"8","author":"Le","year":"2018","journal-title":"Sci Rep."},{"key":"R5-20250728","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archopht.126.1.71","article-title":"Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation","volume":"126","author":"Bachmann","year":"2008","journal-title":"Arch Ophthalmol."},{"key":"R6-20250728","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00417-014-2851-8","article-title":"Three-year corneal graft survival rate in high-risk cases treated with subconjunctival and topical bevacizumab","volume":"253","author":"Dekaris","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"R7-20250728","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00417-009-1099-1","article-title":"Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization","volume":"247","author":"Koenig","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"R8-20250728","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/ICO.0b013e31823f8f7a","article-title":"Angioregressive pretreatment of mature corneal blood vessels before keratoplasty: fine-needle vessel coagulation combined with anti-VEGFs","volume":"31","author":"Koenig","year":"2012","journal-title":"Cornea."},{"key":"R9-20250728","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/ICO.0b013e3182775f8d","article-title":"Topical ranibizumab as a treatment of corneal neovascularization","volume":"32","author":"Ferrari","year":"2013","journal-title":"Cornea."},{"key":"R10-20250728","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jtos.2012.01.005","article-title":"Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin)","volume":"10","author":"Stevenson","year":"2012","journal-title":"Ocul Surf."},{"key":"R11-20250728","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1097\/TXD.0000000000000894","article-title":"Risk of corneal graft rejection after high-risk keratoplasty following fine-needle vessel coagulation of corneal neovascularization combined with bevacizumab: a pilot study","volume":"5","author":"Hos","year":"2019","journal-title":"Transpl Direct."},{"key":"R12-20250728","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/S0161-6420(86)33581-4","article-title":"Corneal argon laser photocoagulation for neovascularization in penetrating keratoplasty","volume":"93","author":"Nirankari","year":"1986","journal-title":"Ophthalmology."},{"key":"R13-20250728","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1136\/bjo.72.12.900","article-title":"Argon laser treatment of lipid keratopathy","volume":"72","author":"Marsh","year":"1988","journal-title":"Br J Ophthalmol."},{"key":"R14-20250728","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/ICO.0000000000002406","article-title":"Corneal crosslinking to regress pathologic corneal neovascularization before high-risk keratoplasty","volume":"40","author":"Schaub","year":"2021","journal-title":"Cornea."},{"key":"R15-20250728","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/00003226-200307000-00018","article-title":"Photodynamic therapy of corneal neovascularization with verteporfin","volume":"22","author":"Fossarello","year":"2003","journal-title":"Cornea."},{"key":"R16-20250728","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ajo.2007.05.028","article-title":"Photodynamic therapy with verteporfin for corneal neovascularization","volume":"144","author":"Yoon","year":"2007","journal-title":"Am J Ophthalmol."},{"key":"R17-20250728","doi-asserted-by":"crossref","first-page":"5862","DOI":"10.1167\/iovs.17-22904","article-title":"Photodynamic therapy leads to time-dependent regression of pathologic corneal (lymph) angiogenesis and promotes high-risk corneal allograft survival","volume":"58","author":"Hou","year":"2017","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"R18-20250728","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ophtha.2011.09.019","article-title":"Risk of corneal transplant rejection significantly reduced with Descemet's membrane endothelial keratoplasty","volume":"119","author":"Anshu","year":"2012","journal-title":"Ophthalmology."},{"key":"R19-20250728","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ophtha.2016.12.017","article-title":"Incidence and clinical course of immune reactions after Descemet membrane endothelial keratoplasty: retrospective analysis of 1000 consecutive eyes","volume":"124","author":"Hos","year":"2017","journal-title":"Ophthalmology."},{"key":"R20-20250728","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.jcjo.2018.04.010","article-title":"Treatment of corneal edema secondary to chemical burn by Descemet membrane endothelial keratoplasty (DMEK)","volume":"54","author":"Hung Le","year":"2019","journal-title":"Can J Ophthalmol."},{"key":"R21-20250728","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/ICO.0000000000002502","article-title":"Descemet membrane endothelial keratoplasty in vascularized eyes: outcome and effect on corneal neovascularization","volume":"40","author":"Hayashi","year":"2021","journal-title":"Cornea."},{"key":"R22-20250728","doi-asserted-by":"crossref","first-page":"11405","DOI":"10.1073\/pnas.0506112103","article-title":"Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision","volume":"103","author":"Cursiefen","year":"2006","journal-title":"Proc Natl Acad Sci U S A."}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0000000000002736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T22:07:03Z","timestamp":1753740423000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0000000000002736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,8]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0000000000002736","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,8]]},"assertion":[{"value":"2020-12-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}